Table of Content

Archive

Autumn 2014, Vol. 22 No. 3

Hong Kong J. Dermatol. Venereol. (2014) 22, 131-134


Case Report

Erosive pustular dermatosis of the scalp following cetuximab

使用西妥昔單抗後,出現糜爛膿皰性頭皮皮膚病一例

P Peters, C Bissex, J Gajra, N Gorddard, D Rubel

Abstract

Cetuximab is a monoclonal antibody that directly inhibits the epidermal growth factor receptor and thus inhibits cell proliferation, angiogenesis and potential metastases whilst promoting apoptosis. Cutaneous reactions are a well documented side effect from the use of epidermal growth factor receptor inhibitors, with a positive relationship established between the severity of the cutaneous adverse reaction and the efficacy of cetuximab. We present a case of 51-year-old male who, after three months use of cetuximab for metastatic colon cancer, presenting with erosive pustular dermatosis of the scalp (EPDS) that improved with the combination of potent topical steroids and oral antibiotics. This is the first recorded presentation of EPDS in association with cetuximab.

西妥昔單抗是一種單克隆抗體,直接抑制表皮生長因子受體,從而抑制細胞增殖、血管生成及轉移的潛力,同時促進細胞凋亡。皮膚反應是使用表皮生長因子受體抑製劑的公認副作用,而西妥昔單抗的功效和皮膚不良反應的嚴重程度有著正相關關係。我們詳述一個五十一歲的男病人,在使用西妥昔單抗治療轉移性結腸癌三個月後,出現糜爛膿皰性頭皮皮膚病,隨著使用強效外用類固醇和口服抗生素組合後,情況得到改善。這是第一次紀錄到糜爛膿皰性頭皮皮膚病與使用西妥昔單抗的關聯。

Keywords: Cetuximab, erosive pustular dermatosis of the scalp

關鍵詞: 西妥昔單抗、糜爛膿皰性頭皮皮膚病